12407 N. MOPAC EXPY., AUSTIN, TX
Investor Presentation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Rein Therapeutics Elects Two Directors and Approves Share Increase
Annual Report to Security Holders
Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics Enters $2.3M Private Placement with Institutional Investors
Director Resignation - Manuel C. Alves Aivado Steps Down from Board
Rein Therapeutics Enters $2.5M Securities Purchase Agreement with Funicular
Q2
Q1
Amended Annual Report
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-1
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Free Writing Prospectus